Breast Cancer: Page 5

Ibex launches study of Galen software for breast cancer
By LabPulse.com staff writers
The research will review the clinical performance of the AI-based Galen Breast algorithm, which helps pathologists detect and grade different types of invasive and noninvasive breast cancer, in a retrospective study. Also, researchers will evaluate use of the software's second-read application and digital workflow in clinical use at Hartford HealthCare, which has 400 locations serving 185 towns and cities.
March 22, 2022
2016 10 05 17 45 45 493 Breast Cancer 400
Paige unveils breast lymph node software at USCAP 2022
By LabPulse.com staff writers
Designed to help pathologists detect if breast cancer has metastasized to the lymph nodes, Paige Breast Lymph Node can yield 98% slide-level sensitivity for detecting metastases of any size, according to the vendor. The software's TissueMap tool highlights all regions on a slide that are suspicious for cancer, and both slides and cases with suspected positive lymph nodes are highlighted to facilitate priority review by pathologists, Paige said.
March 21, 2022
2021 08 18 23 12 2135 Computer Ai Artificial Illustration 400
Theralink lands payment code for advanced breast cancer assay
By LabPulse.com staff writers
Making use of both laser capture microdissection and reverse phase protein array technologies, the Theralink assay measures the tumor cell levels of activated proteins -- the primary targets of most U.S. Food and Drug Administration-approved therapies and biopharmaceutical investigational drugs, according to the company. As a result, oncologists can utilize this potentially predictive molecular tool when selecting appropriate therapies, Theralink said.
March 21, 2022
2021 05 21 20 55 6118 Breast Cancer 3 D 400
Mission Bio opens solid tumor research center at MSK
By LabPulse.com staff writers
Dr. Reis-Filho, PhD, a breast cancer expert and director of experimental pathology at MSK, will run the center in Manhattan. His lab will drive academic and industrial best practices using single-cell DNA profiling to observe tumor heterogeneity and clonal architecture in solid cancers.
March 1, 2022
2019 04 22 23 41 4967 Cancer Cell Target2 400
Lunaphore, MGH collaborate on IVD work for solid tumors
By LabPulse.com staff writers
The collaboration will focus on ovarian, breast, and prostate cancers. The two entities will work together to develop a multiplexed immunofluorescence assay that will measure multiple protein expression.
February 17, 2022
2022 02 18 20 26 7651 2022 02 18 Lunaphore 400
Paige partners with Mindpeak for AI breast cancer software
By LabPulse.com staff writers
Mindpeak's BreastIHC can detect, classify, and quantify breast cancer cells; the platform doesn't require complex setup or calibration procedures, the companies said. BreastIHC can quantify HER2, Ki-67, and the estrogen and progesterone receptors and helps differentiate between tumor and nontumor structures on a single-cell basis, the companies reported.
February 16, 2022
2021 05 21 20 55 6118 Breast Cancer 3 D 400
Agendia, Illumina partner on genomic testing for breast cancer
By LabPulse.com staff writers
Illumina and Agendia plan to develop new tests to enhance the care of breast cancer patients by using the Illumina MiSeqDx sequencing platform to expand the range of gene panels available for solid tumor analysis, Agendia said.
January 10, 2022
2020 01 16 22 39 3973 Dna Sequencing Genome 400
Gestalt, MindPeak deploy AI-based digital pathology algorithm
By LabPulse.com staff writers
The U.S. laboratory is using MindPeak's BreastIHC AI algorithm in routine clinical practice for quantification of breast cancer cells stained with immunohistochemistry (IHC), according to the companies. BreastIHC has been integrated with Gestalt's PathFlow digital pathology software at BioReference, which serves 19 million patients each year.
January 3, 2022
2020 03 11 18 43 2074 Artificial Intelligence Ai Suit 400
Epic Sciences launches blood test for breast cancer patients
By LabPulse.com staff writers
The test features both cell-based and cell-free analysis from a single blood draw, the company said. It detects circulating cancer cells and quantifies estrogen receptor and HER2 proteins in those cells. In addition, it offers whole-genome sequencing of individual circulating tumor cells, and the test analyzes cell-free DNA via next-generation sequencing of 56 genes and can identify genomic alterations.
December 19, 2021
2021 01 12 23 44 3780 Blood Test Samples Lab 400
Biocept touts CSF assay study for identifying HER2 mutations
By LabPulse.com staff writers
The poster, which was selected as a Spotlight Presentation at SABCS, demonstrated CNSide's ability to identify HER2 and other actionable tumor alterations in the CSF of patients with stage IV breast cancer and leptomeningeal disease (LMD), according to the company.
December 12, 2021
2019 07 27 00 04 3609 Breast Cancer Cell 400
Study recommends screening for adults at risk of multiple myeloma
By Leah Sherwood
"We know that in cancers such as breast cancer and lung cancer screening, early detection and early intervention can make a difference in patient survival," senior author Dr. Irene Ghobrial of the Dana-Farber Cancer Institute in Boston said in a statement. "We have shown for the first time that with highly sensitive screening techniques, it may eventually be possible to make a difference in the survival of people at elevated risk for multiple myeloma."
December 10, 2021
2021 12 10 19 28 1244 Ash 2021 Sign 400
Roche introduces 3 breast cancer pathology AI algorithms
By LabPulse.com staff writers
The algorithms, uPath Ki-67 (30-9), uPath ER (SP1), and uPath PR (1E2), aim to be less time-consuming than manual methods of quantification breast cancer biomarkers.
December 7, 2021
2019 07 27 00 04 3609 Breast Cancer Cell 400
Previous Page
Page 5 of 12
Next Page